A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

January 14, 2019

Primary Completion Date

May 21, 2020

Study Completion Date

June 22, 2020

Conditions
Systemic Sclerosis
Interventions
DRUG

GLPG1690

Film-coated tablets of GLPG1690 for oral use.

DRUG

Placebo

Film-coated tablets of GLPG1690 matching placebo for oral use.

Trial Locations (18)

3000

UZ Leuven, Leuven

9000

UZ Gent, Ghent

10117

Charité - Universitätsmedizin Berlin, Berlin

20132

Ospedale San Raffaele S.r.l. - PPDS, Milan

33486

RASF Clinical Research Center, Boca Raton

48109

University of Michigan, Ann Arbor

50439

Azienda Ospedaliero, Florence

60590

Universitätsklinikum Frankfurt, Frankfurt

75231

Metroplex Clinical Research Center, Dallas

77030

UT Physicians Center for Autoimmunity, Houston

90045

Pacific Arthritis Care Center, Los Angeles

90095

UCLA Rheumatology, Los Angeles

02114

Massachusetts General Hospital, Boston

Unknown

Hospital Universitario Vall d'Hebron - PPDS, Barcelona

Hospital Universitario 12 de Octubre, Madrid

Hospital Nuestra Señora de Valme, Seville

L9 7AL

University Hospital Aintree, Liverpool

NW32QG

Royal Free Hospital, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Galapagos NV

INDUSTRY

NCT03798366 - A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis | Biotech Hunter | Biotech Hunter